Industries · 02
Biotech and life sciences.
The business side of the breakthrough, built to clinical pace.
The PILTA lens
Science first. Company close behind.
A clinical-stage company is two organisms: the science, and the business that has to carry it. The science gets the talent and the capital. The business inherits spreadsheets: manual processes, a supply chain improvised around lab schedules, and finance answering to boards from exported files.
PILTA operators build the company around the science: GMP-compliant supply chains, systems that replace the spreadsheet stack, finance discipline that survives diligence, and the operating leadership that lets scientific founders stay scientific.
What we run into most.
GMP from day one
Compliance built into the supply chain before scale makes retrofitting expensive.
Out of the spreadsheets
ERP and systems sized to a clinical-stage company, not a pharma giant.
Diligence-ready finance
Books, forecasts, and reporting that hold up in the data room.
Clinical-phase logistics
Cold chain, vendors, and materials moving on the trial’s calendar, not the other way around.
Partnership readiness
The operational story a partner or acquirer expects to find.
Executive bandwidth
Operating leadership while the founders carry the science and the raise.
Engagement patterns
How engagements run here.
Biotech engagements often begin as a project: an operations assessment, a systems selection, a GMP supply chain build. As trials advance they grow into a fractional executive or an embedded team, because milestones stop waiting.
A typical team pairs an operations lead with supply chain and finance expertise under one operating partner, scaled to the phase you are in.
Straight answers
Questions life-science teams actually ask.
What does a GMP supply chain build-out involve?
Qualified suppliers, controlled materials, documented processes, and traceability from receipt to release. The build is as much documentation discipline as logistics: the goal is a chain an auditor can walk without finding improvisation.
When should a clinical-stage company move off spreadsheets?
Before the spreadsheet becomes the system of record for anything regulated or investor-facing. The move is earlier than most teams think: migrating under pressure, mid-trial or mid-raise, costs far more than migrating early.
What does an operations partner do for a clinical-stage biotech?
The honest version: not slides. The work is standing up the supply chain, the systems, and the finance rhythm the next phase demands, inside the team, at the pace the trial sets.